Siemens Healthineers cuts 2026 outlook - Finance news and analysis from Global Banking & Finance Review
Finance

Siemens Healthineers cuts 2026 outlook

Published by Global Banking & Finance Review

Posted on May 7, 2026

2 min read

· Last updated: May 7, 2026

Add as preferred source on Google

Siemens Healthineers cuts 2026 outlook on Chinese market woes

By Simon Ferdinand Eibach

Siemens Healthineers Revises Financial Projections Amid Market Challenges

May 7 (Reuters) - Siemens Healthineers cut its full-year revenue growth outlook for the 2026 financial year on Thursday, with the company's diagnostics division struggling in China prompting spin-off considerations.

Market Reaction and Share Performance

Shares of the company fell 3.3% after the results were announced.

Impact of Chinese Diagnostics Market

Revenue Decline and Market Share

The Chinese diagnostics market, which accounts for 10% of the company's revenue and is its second largest after the U.S., was hit by lower reimbursement rates and volume-based procurement that depressed prices.

The hit caused the division's revenue to decline by 6.5% to 985 million euros year on year, the company said.

Inflation and Future Expectations

The company also expects more pronounced inflation in the year ahead.

Updated Financial Forecasts

Revenue and Earnings Per Share Outlook

The German medical technology company forecast a revenue growth of between 4.5% and 5.0% from the earlier outlook of between 5% and 6%. The firm also cut its expected earnings per share range to 2.20 to 2.30 euros from 2.20 to 2.40 euros.

Leadership Perspectives and Strategic Considerations

CEO Comments on Diagnostics Division

CEO Bernd Montag said the diagnostics division is facing a "perfect storm" as the segment is also impacted by an ongoing transformation. "We can be an owner of this business, but we don't have to be an owner of this business," Montag said while also highlighting a synergetic core.

Financial Performance and Analyst Expectations

Quarterly Earnings Results

The Erlangen-based company also reported a 3.8% decrease in adjusted earnings before interest and taxes for the second quarter to 5.681 billion euros, missing LSEG consensus expectations of 5.77 billion euros.

Outlook for Chinese Market and Supply Chain Costs

Chief Financial Officer Dr. Jochen Schmitz said in an analyst call that the company saw a significant decline in China in the third quarter of 2025.

Schmitz forecasted additional costs in supply chains at approximately 5 cents per share in profit this year, due in part to memory chips, raw materials and logistics costs.

(Reporting by Simon Ferdinand Eibach; Editing by Nivedita Bhattacharjee and Harikrishnan Nair)

Key Takeaways

  • Diagnostics in China slumped—Diagnostics revenue fell 6.5% in Q2 with margin collapsing to 0.9%, prompting reevaluation of outlook and strategic options for the unit (investing.com).
  • Imaging and Precision Therapy remain resilient—Imaging revenue rose 6.1% and Precision Therapy grew 4.7%, helping buffer broader performance (investing.com).
  • The revised EPS guidance lowered the upper bound from €2.40 to €2.30, while leaving the lower bound unchanged, reflecting cost headwinds and persistent macro pressures (uk.marketscreener.com).

References

Frequently Asked Questions

Why did Siemens Healthineers revise its 2026 outlook?
The company revised its outlook due to weakness in China's diagnostics market and higher inflation.
How does the new earnings per share guidance compare to previous estimates?
The revised earnings per share outlook for 2026 is 2.20-2.30 euros, down from the prior 2.20-2.40 euro range.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category